Neuropsychological impact of trametinib in pediatric low‐grade glioma: A case series

Authors:
Publisher website
Google Scholar
Abstract
Clinical trials of MEK inhibitors are underway in pediatric low‐grade glioma (PLGG) with BRAF oncogene mutations and recurrent/refractory disease. Cognitive and behavioral impacts of MEK inhibitors, such as trametinib, are unknown as these outcomes have not yet been studied. This case series compared cognition and behavior in eight PLGG cases prior to and while on treatment with trametinib compared to four PLGG controls. Intelligence in the trametinib cases was mainly unchanged while on treatment, with mild decline in one of seven cases with complete data. Parent‐reported depression symptoms increased in five of eight trametinib cases relative to one of four controls.

This publication has 16 references indexed in Scilit: